EQS Newswire is a major provider of regulatory and corporate news. It mainly serves companies, investors and media worldwide. Through its services, EQS Newswire enables efficient and secure communication between companies and their stakeholders. Its main services include the distribution of ad hoc announcements, corporate news and the publication of financial reports that meet strict international standards.
Thu, 23.01.2025
Galenica AG
/ Key word(s): Personnel
Galenica nominates Nadine Balkanyi-Nordmann for the Board of Directors 23.01.2025 / 07:00 CET/CEST
Press release
Nadine Balkanyi-Nordmann, an experienced legal, compliance and governance expert, will be recommended for election as a member of the Board of Directors at the next Annual Genera...
Press releaseAd hoc announcement pursuant to Art. 53 LR
Galenica Group sales once again performed very positively in 2024, with growth of 4.7% to CHF 3,922 million. As a result, Galenica outperformed the entire pharmaceutical market in terms of growth (+3.5%, IQVIA, Pharmaceutical Market Switzerland, YTD December 2024).
Following a solid increase ...
Press releaseAd hoc announcement pursuant to Art. 53 LR
Following solid sales growth of 2.6% in the first half of 2024, Galenica grew more strongly again in the third quarter and generated net sales of CHF 2,864.8 million to the end of September 2024. With growth of 4.1%, Galenica outperformed the growth of the overall pharmaceutical market (+2.9%,...
Galenica AG
/ Key word(s): Strategic Company Decision
Expansion of the Executive Committee and handover of the position of CFO 06.08.2024 / 07:00 CET/CEST
Press release
Galenica is aligning its pharmacy business to an even greater focus on customers. With Stephan Mignot, Marketing for the pharmacies will have a direct seat on ...
Press releaseAd hoc announcement pursuant to Art. 53 LR
Galenica Group sales grew by 2.6% to CHF 1,900.0 million in the first half of 2024. Both the “Products & Care” segment and the “Logistics & IT” segment contributed to the sales growth, with growth of 3.1% and 3.0% respectively. As a result, Galenica Group sales developed more dynamical...
Galenica AG
/ Key word(s): Investment
Galenica increases shareholding in Redcare Pharmacy to 10% 22.07.2024 / 18:11 CET/CEST
Press release
Today, Galenica notified the Dutch Authority for the Financial Markets (AFM) of its 10% stake in Redcare Pharmacy N.V.
As part of the strategic partnership between Galenica and Redcare Phar...
Press releaseAd hoc announcement pursuant to Art. 53 LR
The Galenica Group made a good start to the new year with sales growth of 4.8% to CHF 1,255.5 million in the first four months of 2024. All Service Units performed well and contributed to the good sales performance.
The sales growth is based on a positive development of the pharmaceutical ma...
Galenica AG
/ Key word(s): Bond
Galenica successfully places a bond of over CHF 100 million 16.04.2024 / 18:05 CET/CEST
Press release
Today, Galenica successfully placed a fixed rate bond of over CHF 100 million.
The bond has a term of 7 years and an annual coupon of 1.65%. The proceeds from the transaction will be used for g...
Galenica AG
/ Key word(s): AGMEGM
7th Annual General Meeting: Shareholders approve all proposals 10.04.2024 / 17:29 CET/CEST
Press release
The seventh Annual General Meeting of Galenica Ltd. was held on 10 April 2024 at the Kursaal in Bern. The shareholders approved all the proposals put forward by the Board of Directors. They...
Press releaseAd hoc announcement pursuant to Art. 53 LR
The Galenica Group achieved strong growth with an increase in sales of 4.4% in the 2023 financial year and generated consolidated net sales of CHF 3,746.0 million. Adjusted for the extraordinary sales related to COVID-19 (self-tests, COVID-19 vaccinations and rapid tests) in the prior-year per...
You have pressed the "". We would like to inform you that you are now leaving the information service of the portal site ayondo.com. You will be redirected to . After confirming the "Continue" button, you confirm that you have been informed of this. You also confirm that you are carrying out this process of your own free will and that it is not the result of any promotional activity or other influence. Continue to .